Please login to the form below

Not currently logged in
Email:
Password:

Aquapharm awarded GBP 4m funding

Scotland-headquartered Aquapharm Biodiscovery has raised GBP 4m (USD 8m) in funding from equity groups, which include the venture capital arm of Tate & Lyle and Dutch venture capital firm, Aescap.

Scotland-headquartered Aquapharm Biodiscovery has raised GBP 4m (USD 8m) in funding from equity groups, which include the venture capital arm of Tate & Lyle and Dutch venture capital firm, Aescap.

Aquapharm develops antiinfectives from microscopic marine elements and is also developing anti-ageing treatments through advanced fermentation technology.

Shareholders in the company include Scottish and Argyll and Islands Enterprise have also increased investment in Aquapharm.

The company has built up a library of over 6500 marine bacteria and fungi and is using the microorganisms to look for products, such as new antibiotics and "functional" foods with health-giving benefits, such as anti-oxidants.

Dr Simon Barnes, managing partner of Tate & Lyle Ventures, said that Aquapharm had an unrivalled ability to develop natural marine-derived ingredients for a wide range of functional food applications and nutraceuticals, in an interview with a local newspaper.

25th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics